670
Participants
Start Date
October 2, 2018
Primary Completion Date
December 1, 2020
Study Completion Date
December 1, 2020
Safety data collection (following routine vaccination) by a continuous surveillance method.
"This study assesses the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine in terms of frequency and intensity of adverse events (AEs) and serious adverse events (SAEs) when administered routinely in male and female subjects aged between 9 and 25 years, according to the approved Prescribing Information in Korea.~All AEs reported during the 30-day post-vaccination follow-up period (Day 1 to Day 30) and all SAEs reported through the study period from dose 1 up to 30 days after the last dose administered during the post-marketing surveillance (PMS) were collected as part of safety data in this PMS."
GSK Investigational Site, Yangju-si, Gyeonggi-do
GSK Investigational Site, Gyeonggi-do
GSK Investigational Site, Gyeonggi-do
GSK Investigational Site, Suwon-si, Gyeonggi-do
GSK Investigational Site, Suwon-si, Gyeonggi-do
GSK Investigational Site, Incheon
GSK Investigational Site, Gongju-si, Chungcheongnam-do
GSK Investigational Site, Chungcheongnam-do
GSK Investigational Site, Gyeongsangbuk-do
GSK Investigational Site, Gyeongsangbuk-do
GSK Investigational Site, Daegu
GSK Investigational Site, Busan
GSK Investigational Site, Jeollabuk-do
GSK Investigational Site, Jeonju-si,Jeollabuk-do
GSK Investigational Site, Jeollabuk-do
GSK Investigational Site, Gwangju
GSK Investigational Site, Jeonju-si, Jeollabuk-do
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
Lead Sponsor
GlaxoSmithKline
INDUSTRY